{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:31:14Z","timestamp":1792794674249,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T00:00:00Z","timestamp":1562976000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"SHCS","award":["# 816"],"award-info":[{"award-number":["# 816"]}],"id":[{"id":"https:\/\/ror.org\/048hyya13","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["#177499"],"award-info":[{"award-number":["#177499"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SHCS Research Foundation"},{"name":"Yvonne Jacob Foundation"},{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004451","name":"Harry Frank Guggenheim Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004451","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Zurich University Research Priority Program: Evolution in Action: From Genomes to Ecosystems","award":["#U-702-26-01"],"award-info":[{"award-number":["#U-702-26-01"]}],"id":[{"id":"https:\/\/ror.org\/02crff812","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["#BSSGI0_155851"],"award-info":[{"award-number":["#BSSGI0_155851"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002999","name":"Dutch Ministry of Health, Welfare, and Sport","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Centre for Infectious Disease Control"},{"name":"National Institute for Public Health and the Environment","id":[{"id":"https:\/\/ror.org\/01cesdt21","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The impact of the M184V\/I mutation on the virological failure (VF) rate in HIV-positive patients with suppressed viremia switching to an abacavir\/lamivudine\/dolutegravir regimen has been poorly evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This is an observational study from 5 European HIV cohorts among treatment-experienced adults with \u226450 copies\/mL of HIV-1 RNA who switched to abacavir\/lamivudine\/dolutegravir. Primary outcome was the time to first VF (2 consecutive HIV-1 RNA &amp;gt;50 copies\/mL or single HIV-1 RNA &amp;gt;50 copies\/mL accompanied by change in antiretroviral therapy [ART]). We also analyzed a composite outcome considering the presence of VF and\/or virological blips. We report also the results of an inverse probability weighting analysis on a restricted population with a prior history of VF on any ART regimen to calculate statistics standardized to the disparate sampling population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 1626 patients (median follow-up, 288.5 days; interquartile range, 154\u2013441). Patients with a genotypically documented M184V\/I mutation (n = 137) had a lower CD4 nadir and a longer history of antiviral treatment. The incidence of VF was 29.8 cases (11.2\u201379.4) per 1000 person-years in those with a previously documented M184V\/I, and 13.6 cases (8.4\u201321.8) in patients without documented M184V\/I. Propensity score weighting in a restricted population (n = 580) showed that M184V\/I was not associated with VF or the composite endpoint (hazard ratio [HR], 1.27; 95% confidence interval [CI], 0.35\u20134.59 and HR 1.66; 95% CI, 0.81\u20133.43, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In ART-experienced patients switching to an abacavir\/lamivudine\/dolutegravir treatment, we observed few VFs and found no evidence for an impact of previously-acquired M184V\/I mutation on this outcome. Additional analyses are required to demonstrate whether these findings will remain robust during a longer follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofz330","type":"journal-article","created":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T05:45:55Z","timestamp":1562996755000},"source":"Crossref","is-referenced-by-count":30,"title":["Impact of the M184V\/I Mutation on the Efficacy of Abacavir\/Lamivudine\/Dolutegravir Therapy in HIV Treatment-Experienced Patients"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5118-9523","authenticated-orcid":false,"given":"Flaminia","family":"Olearo","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland"},{"name":"Institute of Medical Virology, Swiss National Reference Centre for Retroviruses, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[{"name":"University of Bordeaux, Institut de Sant\u00e9 Publique d\u2019Epid\u00e9miologie et de D\u00e9veloppement (ISPED), U1219 INSERM, France"},{"name":"Centre Hospitalier Universitaire de Bordeaux, Service de M\u00e9decine Interne et Maladies Infectieuses, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Yerly","sequence":"additional","affiliation":[{"name":"Laboratory of Virology, Geneva University Hospitals and Faculty of Medicine, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Wandeler","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine, University Hospital of Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Stoeckle","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital of Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Cavassini","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Lausanne University Hospital, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Scherrer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland"},{"name":"Institute of Medical Virology, Swiss National Reference Centre for Retroviruses, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Costagiola","sequence":"additional","affiliation":[{"name":"INSERM, Sorbonne Universit\u00e9, Institut Pierre Louis d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schmid","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, St. Gallen Cantonal Hospital, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huldrych F","family":"G\u00fcnthard","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland"},{"name":"Institute of Medical Virology, Swiss National Reference Centre for Retroviruses, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enos","family":"Bernasconi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Ospedale Regionale di Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrg","family":"Boeni","sequence":"additional","affiliation":[{"name":"Institute of Medical Virology, Swiss National Reference Centre for Retroviruses, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"D\u2019arminio Monforte","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Institute of Infectious and Tropical Medicine, L\u2019Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo, University of Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, University of Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rossetti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Neau","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Bordeaux, Service de M\u00e9decine Interne et Maladies Infectieuses, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantxika","family":"Bellecave","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Centre Hospitalier Universitaire de Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Rijnders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reiss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Wit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Kouyos","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland"},{"name":"Institute of Medical Virology, Swiss National Reference Centre for Retroviruses, University of Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Calmy","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,12]]},"reference":[{"key":"2020081004465311400_CIT0001","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"2020081004465311400_CIT0002","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2020081004465311400_CIT0003","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"2020081004465311400_CIT0004","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"2020081004465311400_CIT0005","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"2020081004465311400_CIT0006","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/jac\/dku535","article-title":"Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients","volume":"70","author":"Fourati","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020081004465311400_CIT0007","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"2020081004465311400_CIT0008","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial","volume":"4","author":"Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"2020081004465311400_CIT0009","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1132","article-title":"Dolutegravir monotherapy versus dolutegravir\/abacavir\/lamivudine for virologically suppressed people living with chronic HIV infection: the randomized non-inferiority MONCAY trial","author":"Hocqueloux","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020081004465311400_CIT0010","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/S2352-3018(18)30249-2","article-title":"Issues about periconception use of dolutegravir are reminiscent of early concerns about efavirenz","volume":"5","author":"Black","year":"2018","journal-title":"Lancet HIV"},{"key":"2020081004465311400_CIT0011","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/jac\/dky093","article-title":"Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial","volume":"73","author":"Blanco","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020081004465311400_CIT0012","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/hiv.12600","article-title":"Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0","volume":"19","author":"Ryom","year":"2018","journal-title":"HIV Med"},{"key":"2020081004465311400_CIT0013","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1131","article-title":"Non-inferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary HIV infection: a randomized, controlled, multi-site, open-label, non-inferiority trial","author":"Braun","year":"2019;","journal-title":"Clin Infect Dis"},{"key":"2020081004465311400_CIT0014"},{"key":"2020081004465311400_CIT0015","doi-asserted-by":"crossref","first-page":"e0152970","DOI":"10.1371\/journal.pone.0152970","article-title":"Incidence and risk factors for severe bacterial infections in people living with HIV. ANRS CO3 Aquitaine Cohort, 2000\u20132012","volume":"11","author":"Collin","year":"2016","journal-title":"PLOS ONE"},{"key":"2020081004465311400_CIT0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/hiv.12692","article-title":"Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort","volume":"20","author":"Modica","year":"2019","journal-title":"HIV Med"},{"key":"2020081004465311400_CIT0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022516","article-title":"AIDS Therapy Evaluation in the Netherlands (ATHENA) national observational HIV cohort: cohort profile","volume":"8","author":"Boender","year":"2018","journal-title":"BMJ Open"},{"key":"2020081004465311400_CIT0018"},{"key":"2020081004465311400_CIT0019","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ije\/dyp321","article-title":"Cohort profile: the Swiss HIV Cohort Study","volume":"39","author":"The Swiss HIV Cohort Study, Schoeni-Affolter F, Ledergerber B, et al","year":"2010","journal-title":"Int J Epidemiol"},{"key":"2020081004465311400_CIT0020","author":"Center of Excellence for Health, Immunity and Infections. HICEP (HIV Collaboration Data Exchange Protocol)"},{"key":"2020081004465311400_CIT0021","first-page":"1254","article-title":"Switching to raltegravir from a virologically effective boosted protease inhibitor regimen: a comparative effectiveness analysis from the French Hospital Database on HIV (FHDH-ANRS CO4)","volume":"63","author":"Potard","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020081004465311400_CIT0022","first-page":"1","article-title":"A practical guide for using propensity score weighting in R","volume":"20","author":"Olmos","year":"2015","journal-title":"Pract Assessment Res Eval"},{"key":"2020081004465311400_CIT0023","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1089\/aid.2014.0037","article-title":"Worth the weight: using inverse probability weighted Cox models in AIDS research","volume":"30","author":"Buchanan","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020081004465311400_CIT0024","first-page":"656","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Pract Epidemiol"},{"key":"2020081004465311400_CIT0025","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/aje\/kwj047","article-title":"Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect","volume":"163","author":"Kurth","year":"2006","journal-title":"Am J Epidemiol"},{"key":"2020081004465311400_CIT0026","doi-asserted-by":"crossref","first-page":"ofy113","DOI":"10.1093\/ofid\/ofy113","article-title":"Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study","volume":"5","author":"Gagliardini","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2020081004465311400_CIT0027","article-title":"M184V\/I as unique NRTI resistance mutation does not impact the efficacy of an abacavir\/lamivudine\/dolutegravi r use as switch in patients with a fully suppressed viral load.","author":"Marcelin"},{"key":"2020081004465311400_CIT0028","article-title":"Dual regimen with dolutegravir and lamivudine maintains virologic suppression even in heavily treatment-experienced HIV-infected patients: 48-week results from a pilot study (DOLULAM).","author":"Reynes"},{"key":"2020081004465311400_CIT0029","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2020081004465311400_CIT0030","article-title":"DTG VS LPV\/R (DAWNING): Efficacy by baseline NRTI resistance and second -line NRTI use.","author":"Brown"},{"key":"2020081004465311400_CIT0031","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijantimicag.2019.03.016","article-title":"Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients","volume":"54","author":"Chen","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2020081004465311400_CIT0032","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijantimicag.2018.01.009","article-title":"Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations","volume":"51","author":"S\u00f6rstedt","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020081004465311400_CIT0033","article-title":"A phase 3b, open-label, pilot study to evaluate switching to elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and\/or M184I (GS-US-292\u20131824)","author":"Valero"},{"key":"2020081004465311400_CIT0034","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/QAD.0000000000000203","article-title":"HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure","volume":"28","author":"Swenson","year":"2014","journal-title":"AIDS"},{"key":"2020081004465311400_CIT0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1468-1293.2006.00403.x","article-title":"Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy","volume":"7","author":"Sungkanuparph","year":"2006","journal-title":"HIV Med"},{"key":"2020081004465311400_CIT0036","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/00002030-200404300-00005","article-title":"Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia","volume":"18","author":"Karlsson","year":"2004","journal-title":"AIDS"},{"key":"2020081004465311400_CIT0037","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","article-title":"Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study","volume":"18","author":"Hermans","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2020081004465311400_CIT0038","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s12879-015-1120-8","article-title":"Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study","volume":"15","author":"Young","year":"2015","journal-title":"BMC Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofz330\/28933744\/ofz330.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/10\/ofz330\/33598981\/ofz330.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/10\/ofz330\/33598981\/ofz330.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T04:48:17Z","timestamp":1597034897000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz330\/5532016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,12]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz330","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,7,12]]},"article-number":"ofz330"}}